Last reviewed · How we verify
Xolaam®
Xolaam is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation and improve airflow in respiratory disease.
Xolaam is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation and improve airflow in respiratory disease. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).
At a glance
| Generic name | Xolaam® |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
The drug activates beta-2 adrenergic receptors, leading to increased intracellular cAMP levels and smooth muscle relaxation in the airways. This results in sustained bronchodilation and improved lung function. Xolaam is formulated as a long-acting agent designed to provide extended therapeutic effect over 12-24 hours.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (maintenance therapy)
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xolaam® CI brief — competitive landscape report
- Xolaam® updates RSS · CI watch RSS
- AstraZeneca portfolio CI